About vonoprazan
Vonoprazan manufacturers include the originator Takeda, which sells Takecab in Japan and Asia, Phathom Pharmaceuticals, which sells Voquezna in the US under licence, and generic producers in India and other markets. Vonoprazan is a potassium-competitive acid blocker (P-CAB), a newer class of acid suppressant that works faster and more consistently than proton pump inhibitors. It is used for erosive oesophagitis, heartburn and, with antibiotics, Helicobacter pylori infection. Pharmaceutical companies can source vonoprazan tablets and API through out-licensing, supply or technology transfer.
Vonoprazan key facts
|
Property |
Vonoprazan |
|---|---|
|
INN |
Vonoprazan (as fumarate) |
|
Molecular formula / weight |
C17H16FN3O2S / 345.4 g/mol (base) |
|
ATC code |
A02BC08 |
|
Drug class |
Potassium-competitive acid blocker (P-CAB) |
|
Brand names |
Takecab (Takeda, Japan and Asia); Voquezna, Voquezna Triple Pak, Voquezna Dual Pak (Phathom, US) |
|
Originator |
Takeda (Japan) |
|
Dosage form and strengths |
Tablets 10 mg and 20 mg |
|
Indications (US) |
Healing and maintenance of erosive oesophagitis; heartburn in non-erosive reflux disease; H. pylori infection (with antibiotics) |
|
First approval |
Japan, 2014–2015 (Takecab) |
|
US approvals |
H. pylori packs, May 2022; erosive oesophagitis, November 2023; non-erosive reflux heartburn, 2024 |
|
US exclusivity |
NCE exclusivity recognised by FDA through 3 May 2032 |
|
US litigation |
BDR sued the FDA in October 2026 over the exclusivity decision |
|
Generic status |
Generics available in India and other markets; none in the US |
Vonoprazan manufacturers and licensing history
Takeda discovered vonoprazan and launched it in Japan as Takecab in 2015. It became widely used across Asia. In 2019, Phathom Pharmaceuticals licensed the US, European and Canadian rights.
In the US, the FDA approved Voquezna Triple Pak and Dual Pak for H. pylori in May 2022, Voquezna tablets for erosive oesophagitis in November 2023, and heartburn in non-erosive reflux disease in 2024. In June 2025, the FDA recognised 10 years of new chemical entity exclusivity, through 3 May 2032. In October 2026, BDR sued the FDA to challenge that decision, which could allow earlier generics if successful.
Vonoprazan generics are already available in India and some other markets. Buyers should confirm the salt form (fumarate), GMP status, a DMF and the patent and exclusivity position in each target market.
Vonoprazan dosage forms and dossier types
Vonoprazan is approved as 10 mg and 20 mg tablets, and in the US as co-packs with antibiotics.
|
Form |
Strengths |
Typical dossier |
Notes |
|---|---|---|---|
|
Vonoprazan tablets |
10, 20 mg |
US ANDA (after exclusivity); national CTD |
Reference Takecab / Voquezna |
|
Vonoprazan + amoxicillin (+ clarithromycin) packs |
Per label |
US ANDA; national |
H. pylori treatment |
|
Vonoprazan fumarate API |
Bulk |
DMF |
Fumarate salt |
|
Target market |
Dossier format |
Key requirement |
|---|---|---|
|
United States |
ANDA (eCTD) |
NCE exclusivity to 3 May 2032; ongoing litigation |
|
India, Asia, other |
National CTD |
Generics already available in some markets |
|
European Union |
EU CTD |
Check approval and patent status |
Vonoprazan regulatory and patent status
Vonoprazan was approved in Japan in 2014–2015 and in the US from 2022. In June 2025, the FDA recognised NCE exclusivity for Voquezna tablets through 3 May 2032. In October 2026, BDR sued the FDA over this, and Phathom says it will defend the exclusivity. Listed US patents run to 2028–2030. Check current exclusivity, litigation and patents before filing.
Vonoprazan mechanism of action and therapeutic use
Vonoprazan blocks the proton pump in stomach cells by competing with potassium, rather than binding permanently like proton pump inhibitors. It works from the first dose, does not need activation by acid and suppresses acid for longer. Vonoprazan is used for erosive oesophagitis, heartburn and, with antibiotics, H. pylori infection.
Vonoprazan licensing and sourcing
Vonoprazan suppliers and licensing partners typically offer dossier out-licensing, finished-product supply or technology transfer. Buyers usually compare GMP status, salt form, patent and exclusivity position, and territory availability. Current offers and supplier contacts are listed among the vonoprazan manufacturers on Pipelinepharma.
Frequently asked questions about vonoprazan
Who are the main vonoprazan manufacturers? Takeda is the originator and sells Takecab in Japan and Asia. Phathom Pharmaceuticals sells Voquezna in the US. Generic producers make vonoprazan in India and other markets.
When can generic vonoprazan launch in the US? The FDA recognised exclusivity through 3 May 2032. A lawsuit filed in October 2026 challenges this, so the date could change.
What is vonoprazan used for? Vonoprazan is used for erosive oesophagitis, heartburn from reflux disease and, with antibiotics, H. pylori infection.
What forms and strengths of vonoprazan are available? Vonoprazan is available as 10 mg and 20 mg tablets, and in the US as co-packs with antibiotics.
How is vonoprazan different from omeprazole? Both reduce stomach acid. Vonoprazan is a P-CAB that works from the first dose and gives stronger, more consistent acid control than proton pump inhibitors such as omeprazole.
Popular Searches
Want unlimited access to the Pipelinepharma database?
Become a subscriber to unlock:
-
Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.
-
Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.
-
Higher profitability: compare multiple supplier offers and secure the best commercial terms.
-
Expanded network: view supplier portfolios and stay updated on new products.
-
Value-added product ideas: discover products with lower competition potential.
-
Access to marketing authorizations for sale: find already registered products in your target markets.